November 12, 2012 15:08
FAS green-lights AFK Sistema bid to buy 100% of VeroPharm, but with terms (Part 2)
MOSCOW. Nov 12 (Interfax) - Russia's Federal Antimonopoly Service (FAS) has approved AFK Sistema's (RTS: AFKS) request for permission to buy 100% of the stock in pharmaceuticals company OJSC VeroPharm (RTS: VRPH), but has attached some terms, a FAS statement says.
The FAS established that VeroPharm has a dominating position on the market for medicines with MNN Gemifloksatsin, and its subsidiary LLC LENS-Pharm with MNN Poliadenilovaya Kislota + Poliuridilovaya Kislota.
The FAS takes the view that the conduct of this deal could lead to a limiting of access to the market for the sale of these medical preparations by independent counteragent VeroPharm and LENS-Pharm. In light of this, the FAS requires of Sistema and VeroPharm to ensure the fulfillment of all contracts for the delivery of all medicines existing on the date the deal is completed.
Before the deal is done, Sistema is to post on its official website the document regulating its commercial policy as regards VeroPharm medical preparations, and announce changes to commercial policy in letter form to the FAS within thirty days.
The parties are not to, from the date the deal is completed, effect any unfounded economic or technological reduction or halt of the production and supply of goods that are still in demand. They are also to announce to the FAS either of such circumstances in letter form within thirty days.
AFK Sistema and VeroPharm are to annually inform the FAS in letter form that they are meeting these conditions.
The parties to the deal are to announce its completion to the anti-monopoly agency within twenty days from the day the deal is wrapped up.
According to DSM Group data, VeroPharm is third in a rating of the largest Russian pharmaceutical companies. Company product is provided by three plants: in Belgorod, Voronezh, and Pokrov. VeroPharm specializes in the production of Rx medical goods, which account for about 70% of its sales revenues.
Pharmacy Chain 36.6 (RTS: APTK) owns 51.8% of the company.
(Our editorial staff can be reached at email@example.com)
March 23, 2018
RUSSIAN REPRESENTATIVES DENIED ACCESS TO YULIA SKRIPAL TO PROVIDE HER ASSISTANCE - RUSSIAN FOREIGN MINISTRY
RUSSIA EXPRESSES SERIOUS CONCERN AT MEETING WITH CSTO AMBASSADORS OVER ATTEMPTED MURDER OF RUSSIAN CITIZEN YULIA SKRIPAL IN UK - RUSSIAN FOREIGN MINISTRY
RUSSIA HAS NEVER PRODUCED NERVE AGENT CODENAMED IN WEST AS NOVICHOK - RUSSIAN FOREIGN MINISTRY
Eurobond prices fall as Fed hikes rate
RUSSIA HAS NO RELATION TO SALISBURY INCIDENT, COULD NOT HAVE ANY RELATION TO IT IN PRINCIPLE - RUSSIAN FOREIGN MINISTRY
Over 350,000 observers monitor Russian presidential election - CEC
Russian ambassador to Estonia says did not receive evidence of Russia's role in Skripal incident
Central Bank raises 2018 forecast for retail lending growth to 11%-13%, corporate lending forecast reduced to 7%-9%
If inflation gets stuck at 2%-2.5%, Central Bank will take measures to bring it closer to 4% - Nabiullina (Part 2)
Daily Headline News for March 23, 2018
Venezuelan president congratulates Putin on re-election
Russian military scramble fighter jet to intercept foreign reconnaissance aircraft once this week
Russia not striking E. Ghouta, not using incendiary munitions - Defense Ministry
RUSSIA NOT STRIKING EASTERN GHOUTA, NOT TO MENTION THAT IT IS NOT USING INCENDIARY MUNITIONS, UNLIKE U.S.-LED COALITION - RUSSIAN DEFENSE MINISTRY